Trial Profile
Effect of Sarilumab on periodontitis and related biomarkers in rheumatoid arthritis
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Aug 2021
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Periodontitis; Rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms SAPERA
- Sponsors Sanofi Genzyme
- 27 Aug 2021 New trial record